All News
SLE Conference Preview: progress in biologics at #ACR25
We now have four licensed targeted therapies (i.e., belimumab, voclosporin and obinutuzumab for active lupus nephritis and belimumab and anifrolumab for active non-renal SLE). What are other issues to be addressed and https://t.co/uvVICAsCzo
Dr. John Cush RheumNow ( View Tweet)
Lupus in Focus: 2025 ACR Treatment Guidelines for SLE
Dr. Sheila Reyes reports on the scientific session presentation of the #ACR25 treatment guidelines for SLE
https://t.co/Bh1fSFf8ju https://t.co/OH8h9GDeMf
Links:
Dr. John Cush RheumNow ( View Tweet)
Day 4 Recap: ACR Convergence 2025 Highlights https://t.co/CMpbzc4O5x
Great discussion by @EBRheum @AkhilSoodMD @Dr_Brian_MD .
I have always been a FK fan in lupus nephritis as an add on therapy , the only inconvenience is regular monitoring.
@RheumNow
#ACR25
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Prospective RCT on safety & efficacy of TAC+GC vs. MMF+GC
TAC+GC was comparable to MMF+GC as continuous induction maintenance treatment over 96 wks for LN.
AE rates comparable.
TAC - AKI & tremor
MMF - leucopenia
reassuring data.more tx options.
#ACR25 @RheumNow Abs2697 https://t.co/16Fd8zE5dL
sheila RHEUMarampa ( View Tweet)
2465: Dual-target CD19/BCMA CAR-T in refractory SLE (Phase 1)
🔹All pts (n=10) met SRI-4 by wk24
🔹DORIS remission: 5 (wk24), 6 (wk36–48)
🔹Residual proteinuria (n=4); renal bx (n=3) showed resolved IC deposits & inflammation
🔹CRS Grade 1 (n=6); no ICANS
@RheumNow #ACR25
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
#SLE #DORIS #remission is RARE and without #prednisone even rarer
#ASIA #Pacific 5K pts over 10 yrs
A call to do better
82% LLDAS, 70% remission, 31% GC-free remission (REM-0) at least once
abst#595 @ACRheum @RheumNow
#ACRBest https://t.co/OK6sYnqs81
Janet Pope Janetbirdope ( View Tweet)
#Urinary #biomarkers #lupus #nephritis
#Tenascin C -suggests repair, fibrosis, progress of #LN
#IL16, #CD163, & more for LN activity
Sometime a biomarker may replace repeat #kidney #biopsies?
#AMP group #Accelerated #Medicines #Program
#ACR24 @ACRheum @RheumNow abst#851
Janet Pope Janetbirdope ( View Tweet)
When should you order a renal bx in suspected #LN?
Active urinary sediment
Used to be #UPCR 500g/g or more
Abst#772 looked at UPCR 250g/g to 499
71% + LN and half needed Rx
esp if
Low C3,C4
Black race
Petri, Baltimore #lupus #cohort
#ACR25 @ACRheum @RheumNow
Janet Pope Janetbirdope ( View Tweet)
CAR-T Cell Therapies Show Promise for Autoimmune Disease
Two pioneering studies presented at #ACR25 spotlight the potential of CAR-T cell therapies to transform treatment for SLE and other autoimmune diseases. These early findings suggest a new frontier in immune modulation and https://t.co/KdNWmVc4Qc
Dr. John Cush RheumNow ( View Tweet)
Abstract 2694: Neutrophil:Lymphocyte ratio (NLR)- a practical step towards clinical monitoring of interferon?
Log₂NLR significantly correlated with all three IFN signatures across patients with SLE, systemic sclerosis, rheumatoid arthritis, and myositis
@RheumNow #ACR25 https://t.co/ujaOQGvAUV
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
TAC+MMF + GC vs TAC +GC in lupus nephritis (target trial emulation):
🔹Higher total renal response w/ TAC + MMF + GC at 12 mo (59.7% vs 33.3%) consistent in ITT & per-protocol
🔹similar adverse events reported (14.6% vs 16.4%)
@RheumNow #ACR25 https://t.co/Yuql3O9C8X
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
Sooner May Still Be Too Late: Kidney Biopsies in SLE
#ACR25 kicked off with Plenary Session by Michelle Petri (Abstract 0772: Redefining When to Biopsy the Kidney in Patients with SLE. As part of a collaboration with the Accelerating Medicines Partnership, Petri and colleagues https://t.co/bU09vpcDew
Dr. John Cush RheumNow ( View Tweet)
#2659 In a large real-world target trial (>1.3M with T2D), SGLT2 inhibitors, esp dapagliflozin & empagliflozin, were assoc with lower risks of RA, lupus, vasculitis & other autoimmune rheumatic diseases vs DPP-4 inhibitors. Possible immune benefits of SGLT2i? @RheumNow #ACR25
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR25 Abstr#2697 H2H RCT of Tacrolimus + GC vs MMF + GC in #lupus Nephritis in Asia for Induction-Maintenance showed similar efficacy. Different side effects: AKI more in TAC, low WCC & infections in MMF. Informative for services with no access to biologics/Voclosporin @RheumNow https://t.co/V4uWhuqjjW
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Abst 2694:
Post-hoc analysis of Phase 2 PAISLEY SLE trial examined impact of deucravacitinib on renal dysfunction
🔹 Plasma proteins a/w ↑ BILAG renal score and ↓ UPCR --> reduced by WK 32
🔹 Biomarkers inversely related to eGFR were reduced with deucra vs PBO
@RheumNow #ACR25 https://t.co/6CvmQ9lCfS
Links:
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
#ACR25 Clinical Preview by Prof Coates to be applied tomorrow!
GC #steroid burden & Mx
Abstr#738 Survey of #GCA patients in US & EU: 3/4 were still on GC; mean 5.3mg/d
Abstr#1526 International consensus of GC taper in #SLE is available & can be applied in clinic
@RheumNow https://t.co/paw7NGjs4p
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Thank you @drdavidliew & @DrLauraCoates ❤️ for highlighting our work. Super-responders (some were IS-Free) do exist with rituximab in #SLE Abstr#1525 @RheumNow https://t.co/S4mMAYInfT
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
@Yuz6Yusof gets a shout out from Laura Coates in the #ACR25 meeting review for his work on rituximab super-responders in SLE
@RheumNow https://t.co/EKUgmENesX
Links:
David Liew drdavidliew ( View Tweet)
Year in Preview
SLE: 52% subtherapeutic on weight based HCQ dosing
Precision prescribing needed, more so for CKD
@RheumNow #ACR25 Abstract 1722 https://t.co/8WqorQ1xJx
Jiha Lee JihaRheum ( View Tweet)
Hydroxychloroquine in SLE is all about the sweet spot. Not too hot with retinopathy, not too cold with flares, just right by the levels.
Yet drug concentrations and TDM are not commonplace in many places - time for change
Laura Coates in the #ACR25 meeting review @RheumNow https://t.co/oB3ecfSQQc
David Liew drdavidliew ( View Tweet)
